-+ 0.00%
-+ 0.00%
-+ 0.00%

LUCID CAPITAL MARKETS Reiterates Buy on BioXcel Therapeutics, Maintains $66 Price Target

Benzinga·07/15/2025 13:54:53
Listen to the news
LUCID CAPITAL MARKETS analyst Elemer Piros reiterates BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and maintains $66 price target.